AI predicts which patients to test for pancreatic cancer

By staff writers

July 6, 2020 -- Researchers created a model utilizing artificial intelligence (AI) that identified patients at an increased risk for pancreatic cancer who could benefit from early screening with a blood test. They presented their findings from a pilot study using the model on July 2 at the virtual European Society for Medical Oncology (ESMO) World Congress on Gastrointestinal Cancer.

The researchers matched 1,378 patients in the U.K. who developed pancreatic cancer with four people of the same age and sex who developed another type of cancer. They then created a model to predict an individual's cancer risk using the patients' electronic health records data from general physician appointments. The data included the patients' symptoms, diseases, and medications up to two years before their cancer diagnosis.

Dr. Ananya Malhotra. Image courtesy of ESMO press office.

The model accurately predicted which patients under the age of 60 were at a higher risk of developing pancreatic cancer up to 20 months before diagnosis. Based on the findings, one life could be saved for every 1,500 blood tests conducted, the researchers reported.

While the ratio of tests to lives saved is not small enough to be clinically viable just yet, study author Dr. Ananya Malhotra was optimistic the researchers are on the right track.

"It shows that AI holds potential to narrow down the number of people we need to screen," stated Malhotra, a research fellow in statistics at the London School of Hygiene and Tropical Medicine. "We should be able to reduce this quite a lot further by matching pancreatic cancer patients to controls from the general population, which is what we plan to do next."

Broad genetic testing spots inherited mutations in young cancer patients
Younger adult cancer patients with tumors that more typically strike later in life may benefit from genetic testing to pick up on germline mutations,...
Blood test bolsters imaging for staging pancreatic cancer
A multianalyte blood test was useful for diagnosing and staging pancreatic ductal adenocarcinoma, adding information beyond what is available from imaging...
How to manage genetic testing of pancreatic cancer patients
With momentum growing for germline testing of all patients newly diagnosed with pancreatic cancer, experts published a road map in JAMA Oncology...
Lynparza PARP approval opens door to more pancreatic cancer testing
Approval of the drug olaparib (Lynparza, Merck/AstraZeneca) by the U.S. Food and Drug Administration at the end of 2019 paves the way for more testing...
CVS Health paves way for genetic testing of cancer patients
CVS Health is launching a program that will facilitate genetic testing for cancer patients at the point of prescribing to guide personalized treatment...

Copyright © 2020

Last Updated eh 7/6/2020 3:59:03 PM